5,6-DIHYDRO-2,3-DIMETHOXY-6,6-DIMETHYLBENZ[7,8]INDOLIZINO[2,3-B]QUINOXALINE
- Product Name
- 5,6-DIHYDRO-2,3-DIMETHOXY-6,6-DIMETHYLBENZ[7,8]INDOLIZINO[2,3-B]QUINOXALINE
- CAS No.
- 163769-88-8
- Chemical Name
- 5,6-DIHYDRO-2,3-DIMETHOXY-6,6-DIMETHYLBENZ[7,8]INDOLIZINO[2,3-B]QUINOXALINE
- Synonyms
- YM 90709;YM-90709 (YM 90709;YM-90709, 10 mM in DMSO;YM 90709;YM90709;YM-90709;5,6-DIHYDRO-2,3-DIMETHOXY-6,6-DIMETHYLBENZ[7,8]INDOLIZINO[2,3-B]QUINOXALINE;2,3-Dimethoxy-6,6-dimethyl-5,6-dihydrobenzo[7,8]indolizino[2,3-b]quinoxaline;Benz[7,8]indolizino[2,3-b]quinoxaline,5,6-dihydro-2,3-dimethoxy-6,6-dimethyl-;YM-90709,GM-CSF,inhibit,Inhibitor,Interleukin Related,IL-5,eosinophils,IL-5R,JAK2
- CBNumber
- CB6394488
- Molecular Formula
- C22H21N3O2
- Formula Weight
- 359.42
- MOL File
- 163769-88-8.mol
5,6-DIHYDRO-2,3-DIMETHOXY-6,6-DIMETHYLBENZ[7,8]INDOLIZINO[2,3-B]QUINOXALINE Property
- Boiling point:
- 579.6±50.0 °C(Predicted)
- Density
- 1.28±0.1 g/cm3(Predicted)
- storage temp.
- Sealed in dry,Room Temperature
- solubility
- DMF: 10 mg/ml; DMSO: 20 mg/ml; Ethanol: 2 mg/ml
- form
- A crystalline solid
- pka
- 2.74±0.40(Predicted)
- color
- Brown to orange
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Warning
- Hazard statements
-
H302Harmful if swallowed
- Precautionary statements
-
P264Wash hands thoroughly after handling.
P264Wash skin thouroughly after handling.
P270Do not eat, drink or smoke when using this product.
P301+P312IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P330Rinse mouth.
P501Dispose of contents/container to..…
N-Bromosuccinimide Price
- Product number
- 23448
- Product name
- YM-90709
- Purity
- ≥98%
- Packaging
- 5mg
- Price
- $93
- Updated
- 2024/03/01
- Product number
- 23448
- Product name
- YM-90709
- Purity
- ≥98%
- Packaging
- 10mg
- Price
- $166
- Updated
- 2024/03/01
- Product number
- 23448
- Product name
- YM-90709
- Purity
- ≥98%
- Packaging
- 25mg
- Price
- $365
- Updated
- 2024/03/01
- Product number
- 1675
- Product name
- YM90709
- Purity
- ≥99%(HPLC)
- Packaging
- 10
- Price
- $220
- Updated
- 2021/12/16
- Product number
- Y100630
- Product name
- YM90709
- Packaging
- 100mg
- Price
- $650
- Updated
- 2021/12/16
5,6-DIHYDRO-2,3-DIMETHOXY-6,6-DIMETHYLBENZ[7,8]INDOLIZINO[2,3-B]QUINOXALINE Chemical Properties,Usage,Production
Description
YM-90709 is a competitive antagonist of the interleukin-5 (IL-5) receptor that has IC50 values of 1 and 0.57 μM for peripheral human eosinophils and eosinophilic HL-60 clone 15 cells, respectively, in a radioligand binding assay. It inhibits IL-5-induced eosinophil survival (IC50 = 0.45 μM) and JAK2 phosphorylation in vitro. YM-90709 inhibits eosinophil and lymphocyte infiltration (ED50s = 0.32 and 0.12 mg/kg, respectively) into the brochoalveolar lavage fluid (BALF) of rats and eosinophil infiltration (ED50 = 0.05 mg/kg) into the BALF of mice in models of airway inflammation.
Uses
YM 90709, is an interleukin-5 receptor antagonist.
Definition
ChEBI: LSM-2128 is a quinoxaline derivative.
Biological Activity
Novel, selective inhibitor of interleukin-5 (IL-5) binding to its receptor (IC 50 = 0.45-1 mM). Inhibits IL-5-prolonged eosinophil survival and IL-5-induced tyrosine phosphorylation of JAK2 without inhibiting GM-CSF-mediated effects. In vivo, inhibits antigen-induced eosinophil and lymphocyte recruitment in rat airways, without affecting peripheral blood or bone marrow leukocytes.
in vivo
YM-90709 (0.01-10 mg/kg; intravenous injection, 72 hours, Inbred female Brown-Norway (BN) rats) results in the inhibition of antigen-induced infiltration of eosinophils and lymphocytes, but not neutrophils or monocytes, into the bronchoalveolar lavage fluid (BALF) of Brown-Norway (BN) rats[2].
| Animal Model: | Inbred female Brown-Norway (BN) rats and used at 4-6 weeks of age[2]. |
| Dosage: | 0.01, 0.1, 1, 10 mg/kg |
| Administration: | Intravenous injection; 72 hours |
| Result: | Inhibited WBC and eosinophil infiltration in a dose-dependent manner. |
IC 50
IL-5
References
[1] TATSUAKI MOROKATA Toshimitsu Y Kenji Ida. Characterization of YM-90709 as a novel antagonist which inhibits the binding of interleukin-5 to interleukin-5 receptor[J]. International immunopharmacology, 2002, 2 12: Pages 1693-1702. DOI: 10.1016/s1567-5769(02)00191-1
[2] TATSUAKI MOROKATA. Effect of a novel interleukin-5 receptor antagonist, YM-90709 (2,3-dimethoxy-6,6-dimethyl-5,6-dihydrobenzo[7,8]indolizino[2,3-b]quinoxaline), on antigen-induced airway inflammation in BN rats[J]. International immunopharmacology, 2004, 4 7: Pages 873-883. DOI: 10.1016/j.intimp.2004.03.011
[3] TATSUAKI MOROKATA. Effect of a novel interleukin-5 receptor antagonist, YM-90709, on antigen-induced eosinophil infiltration into the airway of BDF1 mice[J]. Immunology letters, 2005, 98 1: Pages 161-165. DOI: 10.1016/j.imlet.2004.11.003
5,6-DIHYDRO-2,3-DIMETHOXY-6,6-DIMETHYLBENZ[7,8]INDOLIZINO[2,3-B]QUINOXALINE Preparation Products And Raw materials
Raw materials
Preparation Products
5,6-DIHYDRO-2,3-DIMETHOXY-6,6-DIMETHYLBENZ[7,8]INDOLIZINO[2,3-B]QUINOXALINE Suppliers
- Tel
- --
- Fax
- --
- sales@chemos-group.com
- Country
- Germany
- ProdList
- 6350
- Advantage
- 71
View Lastest Price from 5,6-DIHYDRO-2,3-DIMETHOXY-6,6-DIMETHYLBENZ[7,8]INDOLIZINO[2,3-B]QUINOXALINE manufacturers
- Product
- 5,6-DIHYDRO-2,3-DIMETHOXY-6,6-DIMETHYLBENZ[7,8]INDOLIZINO[2,3-B]QUINOXALINE 163769-88-8
- Price
- US $1.00/g
- Min. Order
- 1g
- Purity
- 99%
- Supply Ability
- 20kg
- Release date
- 2019-12-23